. Author manuscript; available in PMC: 2023 Mar 1.

Published in final edited form as: Am J Obstet Gynecol. 2021 Sep 10;226(3):335–346. doi: 10.1016/j.ajog.2021.09.002

Table 4:

Research Priorities for the Management of Hepatitis B and C in Pregnancy

Hepatitis B	Hepatitis C
Optimize timing of initiation and duration of antiviral therapy to minimize vertical transmission	Development of a safe and effective preventive vaccine
Impact of HBV infection and role of antiviral therapy in improving preterm delivery rates and other birth outcomes	Identify antivirals with safety and efficacy in pregnancy and breastfeeding
Safety and efficacy of tenofovir alafenamide in pregnancy and breastfeeding	Optimize screening guidelines to maximize identification of pregnant women with HCV
Identify subset of women with HBV for whom cesarean delivery may reduce vertical transmission risk	Develop HCV targeted risk reduction for pregnant women who use injection drugs
Reducing/eliminating cold chain requirements for birth dose HBV vaccine	Improve follow up testing rates and identify new prevention options for HCV-exposed infants
Improve uptake of universal birth dose vaccine at delivery	Expand treatment access to women of reproductive age with substance use